ES2392391T3 - Método para modular la activación de macrófagos - Google Patents

Método para modular la activación de macrófagos Download PDF

Info

Publication number
ES2392391T3
ES2392391T3 ES99903869T ES99903869T ES2392391T3 ES 2392391 T3 ES2392391 T3 ES 2392391T3 ES 99903869 T ES99903869 T ES 99903869T ES 99903869 T ES99903869 T ES 99903869T ES 2392391 T3 ES2392391 T3 ES 2392391T3
Authority
ES
Spain
Prior art keywords
compound
use according
pharmaceutically acceptable
disease
neuronal cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99903869T
Other languages
English (en)
Spanish (es)
Inventor
Celine Morissette
Francine Gervais
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BHI LP
Bellus Health International Ltd
Original Assignee
BHI LP
Bellus Health International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BHI LP, Bellus Health International Ltd filed Critical BHI LP
Application granted granted Critical
Publication of ES2392391T3 publication Critical patent/ES2392391T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
ES99903869T 1998-02-11 1999-02-11 Método para modular la activación de macrófagos Expired - Lifetime ES2392391T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US7429598P 1998-02-11 1998-02-11
US24839699A 1999-02-10 1999-02-10
US248396 1999-02-10
PCT/IB1999/000354 WO1999040909A1 (en) 1998-02-11 1999-02-11 Method for modulating macrophage activation
US74295P 2008-06-20

Publications (1)

Publication Number Publication Date
ES2392391T3 true ES2392391T3 (es) 2012-12-10

Family

ID=26755484

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99903869T Expired - Lifetime ES2392391T3 (es) 1998-02-11 1999-02-11 Método para modular la activación de macrófagos

Country Status (12)

Country Link
EP (1) EP1054664B1 (https=)
JP (1) JP4574845B2 (https=)
AU (1) AU2437899A (https=)
CA (2) CA2320224C (https=)
CY (1) CY1113205T1 (https=)
DK (1) DK1054664T3 (https=)
ES (1) ES2392391T3 (https=)
IL (1) IL137751A0 (https=)
MX (2) MXPA00007815A (https=)
NZ (2) NZ550199A (https=)
PT (1) PT1054664E (https=)
WO (1) WO1999040909A1 (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605938A (en) 1991-05-31 1997-02-25 Gliatech, Inc. Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate
WO1999059571A1 (en) * 1998-05-15 1999-11-25 Neurochem, Inc. Use of amyloid inhibitors for modulating neuronal cell death
US6310073B1 (en) 1998-07-28 2001-10-30 Queen's University At Kingston Methods and compositions to treat glycosaminoglycan-associated molecular interactions
CA2369997C (en) * 1999-04-28 2009-11-17 Queen's University At Kingston Compositions and methods for treating amyloidosis
AU5994900A (en) * 1999-07-09 2001-01-30 Isis Innovation Limited Compounds for inhibiting diseases and preparing cells for transplantation
IL150374A0 (en) 1999-12-23 2002-12-01 Neurochem Inc Compounds and methods for modulating cerebral amyloid angiopathy
US7105336B2 (en) * 2002-10-07 2006-09-12 Biogaia Ab Selection and use of lactic acid bacteria for reducing inflammation caused by Helicobacter
EP1585520A1 (en) * 2002-12-24 2005-10-19 Neurochem (International) Limited Therapeutic formulations for the treatment of beta-amyloid related diseases
CN100571701C (zh) * 2002-12-24 2009-12-23 贝卢斯健康(国际）有限公司 治疗β淀粉样蛋白相关疾病的治疗性制品
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US7414076B2 (en) 2003-06-23 2008-08-19 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US7244764B2 (en) 2003-06-23 2007-07-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US20050142191A1 (en) 2003-06-23 2005-06-30 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
EP1646659B1 (en) * 2003-06-23 2014-05-14 Kiacta Sàrl Method for the preparation of 1,3-propane disulfonic acid compounds
US7253306B2 (en) 2003-06-23 2007-08-07 Neurochem (International) Limited Pharmaceutical drug candidates and methods for preparation thereof
WO2006085149A2 (en) 2004-12-22 2006-08-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
TW200716088A (en) * 2005-04-15 2007-05-01 Neurochem Int Ltd Formulations and methods for treating amyloidosis
RU2432362C2 (ru) 2005-11-30 2011-10-27 Эбботт Лэборетриз Моноклональные антитела и их применения
PL2289909T3 (pl) 2005-11-30 2015-04-30 Abbvie Inc Sposób przeszukiwania, proces oczyszczania niedyfundujących oligomerów Abeta, selektywne przeciwciała przeciw niedyfundującym oligomerom Abeta i sposób wytwarzania tych przeciwciał
EP1968561B8 (en) 2005-12-22 2010-10-20 Kiacta Sàrl Treatment of diabetic nephropathy
PT2089417E (pt) 2006-10-12 2015-04-14 Bhi Ltd Partnership Métodos, compostos, composições e veículos para administrar o ácido 3-amino-1-propanossulfónico
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2124952A2 (en) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
RS53174B (sr) 2007-10-05 2014-06-30 Genentech Inc. Upotreba antiamiloidnog beta antitela u slučaju oboljenja oka
JP2012517822A (ja) * 2009-02-19 2012-08-09 ガラパゴス・ナムローゼ・フェンノートシャップ 炎症を包含する疾患の診断及び治療に有用な同定方法及び化合物
MY159626A (en) * 2009-09-17 2017-01-13 Bespoke Bioscience Llc Role of n-2-hydroxy-ethyl-piperazine-n'-2-ethane sulfonic acid (hepes) in pain control and reversal of demyelinization injury
ES2684475T3 (es) 2010-04-15 2018-10-03 Abbvie Inc. Proteínas que se unen a beta amiloide
RU2607368C2 (ru) 2010-07-30 2017-01-10 Ац Иммуне С.А. Безопасные и функциональные гуманизированные антитела
CN103298833B (zh) 2010-08-14 2015-12-16 Abbvie公司 β淀粉样蛋白结合蛋白
WO2016163886A2 (en) * 2015-04-10 2016-10-13 Clues2Cure International B.V. Administration of taurine or an analog thereof for the treatment of nerve cell damage
CN109381452A (zh) * 2017-08-11 2019-02-26 江西青峰药业有限公司 乙基硫酸类化合物的应用及其制备方法
CN109381453A (zh) * 2017-08-14 2019-02-26 江西青峰药业有限公司 乙基硫酸钾在制备用于预防或治疗炎症性疾病药物中的应用
CN109394746A (zh) * 2017-08-15 2019-03-01 江西青峰药业有限公司 乙基硫酸铵在制备用于预防或治疗炎症性疾病药物中的应用
US20250345298A1 (en) 2022-04-28 2025-11-13 Alzheon, Inc. Apoe4 correctors and methods of use
CN120641092A (zh) 2022-12-02 2025-09-12 阿尔泽恩股份有限公司 用于用曲米沙特治疗神经变性病症的方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1144937A (en) * 1977-12-22 1983-04-19 Dke J.E. Helgstrand Aromatic derivatives, pharmaceutical compositions and methods for combatting virus infections
US5087618A (en) * 1982-05-18 1992-02-11 University Of Florida Redox carriers for brain-specific drug delivery
US5463092A (en) * 1989-11-22 1995-10-31 Vestar, Inc. Lipid derivatives of phosphonacids for liposomal incorporation and method of use
US5276059A (en) * 1992-07-10 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of diseases associated with amyloid formation
DE69434571T2 (de) * 1993-03-29 2006-08-03 Queen's University At Kingston, Kingston Propan-1,3-disulphonsäure und deren pharmazeutisch akzeptable Salze zur Behandlung von Amyloidosis
US5643562A (en) * 1993-03-29 1997-07-01 Queen's University Of Kingston Method for treating amyloidosis
US5840294A (en) * 1993-03-29 1998-11-24 Queen's University At Kingston Method for treating amyloidosis
NZ550116A (en) * 1997-08-18 2008-03-28 Neurochem Int Ltd Phosphono-carboxylate compounds for treating amyloidosis
US5869469A (en) * 1997-08-18 1999-02-09 Queen's University At Kingston Phosphonocarboxylate compounds for treating amyloidosis

Also Published As

Publication number Publication date
PT1054664E (pt) 2012-11-02
DK1054664T3 (da) 2012-11-05
MXPA00007815A (es) 2002-04-24
CY1113205T1 (el) 2016-04-13
NZ550199A (en) 2008-07-31
CA2320224C (en) 2008-08-12
AU2437899A (en) 1999-08-30
WO1999040909A1 (en) 1999-08-19
EP1054664B1 (en) 2012-08-08
CA2632106A1 (en) 1999-08-19
EP1054664A1 (en) 2000-11-29
NZ568553A (en) 2010-02-26
CA2320224A1 (en) 1999-08-19
IL137751A0 (en) 2001-10-31
JP2002502871A (ja) 2002-01-29
JP4574845B2 (ja) 2010-11-04
MX2008014823A (es) 2009-03-06
HK1032915A1 (en) 2001-08-10

Similar Documents

Publication Publication Date Title
ES2392391T3 (es) Método para modular la activación de macrófagos
ES2283071T3 (es) Modulacion de la carga de medicamenteos en liposomas multivesiculares.
US11357724B2 (en) Pharmaceutical composition, preparation and uses thereof
RU2215522C2 (ru) Способ эпидурального введения терапевтических соединений с поддерживаемой скоростью высвобождения, способ уменьшения угнетения дыхания
Kreuter Liposomes and nanoparticles as vehicles for antibiotics
KR102666251B1 (ko) 약학적 조성물, 이의 제조 및 용도
EP1496860A1 (en) Localized non-invasive biological modulation system
WO1999002139A1 (en) Methods for universally distributing therapeutic agents to the brain
US11471410B2 (en) Pharmaceutical composition combining at least two distinct nanoparticles and a pharmaceutical compound, preparation and uses thereof
TW201628639A (zh) 醫藥組合物、其製備及其用途
Bagmar et al. A review on targeted drug delivery system
US8753673B2 (en) Liposome composition for delivery of a therapeutic agent to eyes
Hwang Targeted delivery of erythropoietin hybridized with magnetic nanocarriers for the treatment of central nervous system injury: A literature review
Derman et al. Brain-Targeted Nano-Drug Delivery for the Treatment of Parkinson's Disease
Swain et al. Current Approaches to Smart Drug Delivery
HK1032915B (en) Method for modulating macrophage activation
WO2011036619A2 (en) Two step ultrasound protocol for drug delivery
AbouElhassan et al. Prospective role of Citicoline and nanotechnology as drug delivery approaches for Alzheimer’s disease: Review of the literature
Kumar et al. A Detailed Review on Biodegradable Drug Delivery Systems
Sharma et al. Preparation and Evaluation of Gliptin Liposomes for Targetting Ocular Region in Neurodegeneration
Elzwi Genesis Journal of Surgery and Medicine
Paudel et al. Recent advancement in drug delivery system
Sena’a et al. World of Science: Journal on Modern Research Methodologies
EP4132469A1 (en) Administration of mtor inhibitors into the central nervous system
AU2002362611A1 (en) Localized non-invasive biological modulation system